Methods for regulating gastrointestinal motility

• US 5,795,861 A
• Filed: 06/05/1995
• Issued: 08/18/1998
• Est. Priority Date: 09/07/1993
• Status: Expired due to Term

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Kolterman, Orville G., Rink, Timothy J.
• Primary Examiner(s): Hill, Jr., Robert J.
• Assistant Examiner(s): HARLE, JENNIFER I
• Application Number:
  US08/471,675
• Time in Patent Office: 1,170 Days
• Field of Search: 514/12, 514/11, 514/13, 514/866, 530/304, 530/324
• US Class Current: 514/6.9
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/23 Calcitonins
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/06 Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.

Claims

1. A method of treating gastric hypomotility in a subject comprising administering to said subject a therapeutically effective amount of an amylin antagonist.

3. The method of claim 1 or 2 wherein said hypomotility is a consequence of diabetic neuropathy.

4. The method of claim 1 or 2 wherein said hypomotility is a consequence of anorexia nervosa.

5. A method according to any of claims 1-4 wherein said amylin antagonist is an amylin receptor antagonist.

6. A method according to claim 5 wherein said amylin antagonist is acetyl-¹¹,18 Arg, ³⁰ Asn, ³² Tyr-^9-32 calcitonin(salmon) SEQ. ID. NO.3!.

2. A method of accelerating gastric emptying in a subject comprising administering to said subject a therapeutically effective amount of an amylin antagonist.